$4.79
-0.09-1.84%
Last update: Nov 9, 9:07 AM
Kyverna Therapeutics Inc (KYTX) Stock Price, Quote, News & History
KYTXNASDAQ
Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.
You can purchase shares of Kyverna Therapeutics (NASDAQ:KYTX) through any online brokerage.
Other companies in Kyverna Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Kyverna Therapeutics has a consensus price target of $21.67.
The stock price for Kyverna Therapeutics (NASDAQ: KYTX) is $4.79 last updated November 9, 2026 at 9:07 AM EST.
There are no upcoming dividends for Kyverna Therapeutics.
Kyverna Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Kyverna Therapeutics.
Kyverna Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made...
